Key result
The platelet reactivity index successfully identified nonresponders to acetylsalicylic acid and correlated well with RT-H and PFA-100.
Why the study?
Does the Platelet Reactivity Index accurately identify nonresponders to acetylsalicylic acid therapy compared to other platelet function tests?
Observational
Does the Platelet Reactivity Index accurately identify nonresponders to acetylsalicylic acid therapy compared to other platelet function tests?
The Platelet Reactivity Index is a rapid, inexpensive, and highly predictive method for evaluating response to acetylsalicylic acid therapy, though it cannot determine overdosage.
Answers are grounded in this paper and cite their sources.
May support platelet reactivity index for ASA nonresponse detection; hypothesis-generating and should not change practice without prospective trials.
In 1974, Wu and Hoak described a method for determining circulating platelet aggregates. This method was modified by Grotemeyer in 1983. The platelet reactivity index (PR) is based on the ratio of platelet aggregates in blood samples obtained in different buffer solutions. Platelet aggregates are resolved when blood is sampled in EDTA-buffer, but remain fixed when EDTA-formalin-buffer is used. Generally, the PR is preferred, because in vitro manipulations of platelets are not necessary, and the results are calculated. PR values above 1.05 are suspicious for elevated platelet aggregation. PR values above 1.2 indicate pathological changes in platelet aggregation. The PR is inexpensive (4.0 euro dollars) and rapid to perform. PR values were used successfully to identify nonresponders to secondary prophylaxis with acetylsalicylic acid (ASA), that is, patients suffering from stroke (33%) and patients after cardiac ischemia (18%). Furthermore, elevated PR values correlated significantly with the incidence of arterial thromboembolic complications. The PR correlated well in our prospective study with values received from the retention test Homburg (RT-H) and the platelet function analyzer (PFA-100). The data indicate that the values of the PR seem to be highly predictive for the evaluation of the ASA therapy. However, the PR is not feasible for the determination of the ASA overdosage.
No takes yet. Share an insight, caveat, or question.
Koscielny et al. (2005) conducted an observational in Secondary prophylaxis with acetylsalicylic acid (stroke and cardiac ischemia). Platelet Reactivity Index (PR) was evaluated on Identification of ASA nonresponders and correlation with RT-H and PFA-100. The platelet reactivity index successfully identified nonresponders to acetylsalicylic acid and correlated well with RT-H and PFA-100.
Synapse has enriched 10 related papers. Consider them for comparative context: